JPMorgan Chase & Co. Upgrades BioNTech (NASDAQ:BNTX) to Neutral

BioNTech (NASDAQ:BNTX) was upgraded by equities research analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research note issued to investors on Monday, Briefing.com reports. The firm presently has a $125.00 price target on the stock, up from their prior price target of $91.00. JPMorgan Chase & Co.‘s target price suggests a potential upside of 1.30% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price target on the stock in a research report on Wednesday, August 7th. HSBC upgraded shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. HC Wainwright restated a “buy” rating and set a $113.00 target price on shares of BioNTech in a research report on Tuesday, August 27th. Finally, Jefferies Financial Group upped their target price on shares of BioNTech from $90.00 to $96.00 and gave the company a “hold” rating in a research report on Friday. Seven equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.83.

BioNTech Stock Up 17.5 %

BNTX opened at $123.40 on Monday. The firm’s 50-day simple moving average is $87.28 and its 200-day simple moving average is $89.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. BioNTech has a twelve month low of $76.53 and a twelve month high of $125.41. The firm has a market cap of $29.34 billion, a price-to-earnings ratio of 246.80 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing the consensus estimate of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The firm had revenue of $128.70 million during the quarter, compared to the consensus estimate of $134.98 million. During the same period in the previous year, the company posted ($0.86) EPS. The firm’s revenue for the quarter was down 23.3% compared to the same quarter last year. Equities research analysts anticipate that BioNTech will post -2.8 EPS for the current fiscal year.

Institutional Trading of BioNTech

Hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC raised its holdings in BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after buying an additional 150 shares during the period. Frazier Financial Advisors LLC acquired a new stake in BioNTech during the 4th quarter worth approximately $30,000. Covestor Ltd raised its holdings in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after buying an additional 133 shares during the period. EverSource Wealth Advisors LLC raised its holdings in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares during the period. Finally, Crewe Advisors LLC acquired a new stake in shares of BioNTech in the first quarter valued at approximately $75,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.